Share on StockTwits

BioCryst Pharmaceuticals (NASDAQ:BCRX) CFO Thomas R. Staab II sold 3,125 shares of the company’s stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $12.49, for a total value of $39,031.25. Following the completion of the transaction, the chief financial officer now directly owns 144,301 shares in the company, valued at approximately $1,802,319. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of analysts have recently weighed in on BCRX shares. Analysts at Wells Fargo & Co. upgraded shares of BioCryst Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday. They now have a $17.00 price target on the stock, down previously from $19.00. Separately, analysts at HC Wainwright raised their price target on shares of BioCryst Pharmaceuticals from $21.00 to $24.00 in a research note on Friday, May 30th. They now have a “buy” rating on the stock. Finally, analysts at Roth Capital raised their price target on shares of BioCryst Pharmaceuticals from $18.00 to $20.00 in a research note on Wednesday, May 28th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $18.13.

Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) traded down 0.42% on Tuesday, hitting $11.95. The stock had a trading volume of 1,238,218 shares. BioCryst Pharmaceuticals has a 52 week low of $1.42 and a 52 week high of $13.33. The stock’s 50-day moving average is $9.87 and its 200-day moving average is $9.64. The company’s market cap is $717.8 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.17) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.17). The company had revenue of $3.50 million for the quarter, compared to the consensus estimate of $3.34 million. During the same quarter last year, the company posted ($0.09) earnings per share. BioCryst Pharmaceuticals’s revenue was down 2.8% compared to the same quarter last year. Analysts expect that BioCryst Pharmaceuticals will post $-0.75 EPS for the current fiscal year.

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) is a biotechnology company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.